🇺🇸 Mirum Pharmaceuticals, Inc.MIRM

Company Update Form 8-K 10-11-2026 07:41:28 EST

Subject: 8-K Items 8.01

Overview: Met the primary endpoint in the Phase 3 AZURE-4 study evaluating brelovitug for chronic HDV, with 59% of 300 mg QW patients achieving efficacy.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest